TRADETALKER referring to conversation with NIH Dr.David Danforth...
David Danforth, Jr., M.S., M.D., Surgery Branch Senior Investigator at the National Institute of Health. He was quoted in an SNDY PR saying: "The cytology retrieval kit which contains miniature brushes and a mini aspiratoris, in my opinion, the best method for retrieving cell samples from the lining of the mammary duct".
SNDY's endoscopy instruments have been at NIH for 6-8 years. Dr. Danforth has performed "hundreds" of procedures using SNDY instruments, and there have been several publications coming out of that work (http://www.ncbi.nlm.nih.gov/m/pubmed/17048242/).
I had emailed him 10 days ago and didn't expect a phone call - so was pretty surprised to get a call at my office. I thought he'd be curt, hurried - no way. He was open and conversational, and left no doubt about what Solos (he pronounced it Solas) had meant for his research and for breast cancer diagnosis in general. He said the imagery obtained was crisp, clear, striking. He said they can penetrate 10-15 cm, screening for lesions or other abnormalities. He said it has moved diagnosis and treatment far beyond where it had been 10-15 years ago. NIH's research focus is outlined in this link - he explained this in detail but I can't do it justice:
He knew of Japanese and German firms who carried similar products, but they are far more expensive ($100K range); whereas Solos's system is around $30K. All of the NIH instruments, cameras, video equipment, etc., have been purchased from Solos. He said he did not know of anyone else carring these products in the US. Dr. Danforth said he enjoyed working with Solos, found them responsive, and said there instruments last a very long time. There was absolutely nothing in this conversation that cast any doubt on the quality, integrity, or status of the company. Obviously to the contrary - it confirmed to me that SNDY is critical to breast cancer research at NIH and elsewhere. Dr. Danforth gave me the names of several other MDs who are using endoscopy for more clinical breast cancer diagnosis; I'll be making some calls next week.
This was a really refreshing departure from all of the pps related angst on this board, mine included. SNDY has had and is having a real impact on a critical disease - I had heard that but now believe it. Solid long.
Tradetalker Wednesday, May 23, 2012 11:05:26 AM Re: Wildkite post# 40188 Post # of 43297
Wildkite, nice post, glad you delayed your gym trip. My sentiments exactly, I think this is a story stock. I keep going back to my conversation with Dr. David Danforth at NIH 3 weeks ago. That call changed my entire outlook on this stock. NIH researchers rely exclusively on SNDY instrumentation for fiber ductoscopy, as applied to breast cancer detection, diagnosis, intraductal breast biopsies, and related research. Dr. Danforth and his team have used SNDY products for 6-8 years. He was aware of competitors, but SNDY beats them easily on cost and quality. He knew the company well, spoke highly of not only their products, but the people. SNDY products have literally changed breast cancer research. That was much more than I expected to hear. Combined with a timeline now for CE Mark, probable partnerships, SteriTap release, well, let's just say very exciting times ahead.
Market Data 
Markets 
AI
